[(18)F]Fluorodeoxyglucose Positron Emission Tomography Reveals a Complete Remission of Refractory Metastatic Melanoma after Therapy with Ipilimumab

Ipilimumab (YERVOY) is a monoclonal CTLA-4-antibody with anti-tumor-immunogenic effect and is used to treat malignant melanoma. In this case study, we present [(18)F]Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) images of a 37-year-old woman with metastatic melanoma, who was previously t...

Descripción completa

Detalles Bibliográficos
Autores principales: Yordanova, Anna, Schlenkhoff, Carl, Palmedo, Holger, Essler, Markus, Ahmadzadehfar, Hojjat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
Interesting Image
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5317078/
https://www.ncbi.nlm.nih.gov/pubmed/28242993
http://dx.doi.org/10.4103/0972-3919.198490
_version_ 1782508945870422016
author Yordanova, Anna
Schlenkhoff, Carl
Palmedo, Holger
Essler, Markus
Ahmadzadehfar, Hojjat
author_facet Yordanova, Anna
Schlenkhoff, Carl
Palmedo, Holger
Essler, Markus
Ahmadzadehfar, Hojjat
author_sort Yordanova, Anna
collection PubMed
description Ipilimumab (YERVOY) is a monoclonal CTLA-4-antibody with anti-tumor-immunogenic effect and is used to treat malignant melanoma. In this case study, we present [(18)F]Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) images of a 37-year-old woman with metastatic melanoma, who was previously treated with interferon-alpha therapy and dacarbazine and still progressed. After four cycles of ipilimumab, there was a complete remission of the disease with no evidence of vital, FDG-positive tumor tissue. The follow-up for a total of 1 year confirmed the therapeutic success. This report demonstrates that FDG-PET/CT is a reliable imaging method for response monitoring in metastatic melanoma treated with ipilimumab.
format Online
Article
Text
id pubmed-5317078
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-53170782017-02-27 [(18)F]Fluorodeoxyglucose Positron Emission Tomography Reveals a Complete Remission of Refractory Metastatic Melanoma after Therapy with Ipilimumab Yordanova, Anna Schlenkhoff, Carl Palmedo, Holger Essler, Markus Ahmadzadehfar, Hojjat Indian J Nucl Med Interesting Image Ipilimumab (YERVOY) is a monoclonal CTLA-4-antibody with anti-tumor-immunogenic effect and is used to treat malignant melanoma. In this case study, we present [(18)F]Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) images of a 37-year-old woman with metastatic melanoma, who was previously treated with interferon-alpha therapy and dacarbazine and still progressed. After four cycles of ipilimumab, there was a complete remission of the disease with no evidence of vital, FDG-positive tumor tissue. The follow-up for a total of 1 year confirmed the therapeutic success. This report demonstrates that FDG-PET/CT is a reliable imaging method for response monitoring in metastatic melanoma treated with ipilimumab. Medknow Publications & Media Pvt Ltd 2017 /pmc/articles/PMC5317078/ /pubmed/28242993 http://dx.doi.org/10.4103/0972-3919.198490 Text en Copyright: © 2017 Indian Journal of Nuclear Medicine http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Interesting Image
Yordanova, Anna
Schlenkhoff, Carl
Palmedo, Holger
Essler, Markus
Ahmadzadehfar, Hojjat
[(18)F]Fluorodeoxyglucose Positron Emission Tomography Reveals a Complete Remission of Refractory Metastatic Melanoma after Therapy with Ipilimumab
title [(18)F]Fluorodeoxyglucose Positron Emission Tomography Reveals a Complete Remission of Refractory Metastatic Melanoma after Therapy with Ipilimumab
title_full [(18)F]Fluorodeoxyglucose Positron Emission Tomography Reveals a Complete Remission of Refractory Metastatic Melanoma after Therapy with Ipilimumab
title_fullStr [(18)F]Fluorodeoxyglucose Positron Emission Tomography Reveals a Complete Remission of Refractory Metastatic Melanoma after Therapy with Ipilimumab
title_full_unstemmed [(18)F]Fluorodeoxyglucose Positron Emission Tomography Reveals a Complete Remission of Refractory Metastatic Melanoma after Therapy with Ipilimumab
title_short [(18)F]Fluorodeoxyglucose Positron Emission Tomography Reveals a Complete Remission of Refractory Metastatic Melanoma after Therapy with Ipilimumab
title_sort [(18)f]fluorodeoxyglucose positron emission tomography reveals a complete remission of refractory metastatic melanoma after therapy with ipilimumab
topic Interesting Image
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5317078/
https://www.ncbi.nlm.nih.gov/pubmed/28242993
http://dx.doi.org/10.4103/0972-3919.198490
work_keys_str_mv AT yordanovaanna 18ffluorodeoxyglucosepositronemissiontomographyrevealsacompleteremissionofrefractorymetastaticmelanomaaftertherapywithipilimumab
AT schlenkhoffcarl 18ffluorodeoxyglucosepositronemissiontomographyrevealsacompleteremissionofrefractorymetastaticmelanomaaftertherapywithipilimumab
AT palmedoholger 18ffluorodeoxyglucosepositronemissiontomographyrevealsacompleteremissionofrefractorymetastaticmelanomaaftertherapywithipilimumab
AT esslermarkus 18ffluorodeoxyglucosepositronemissiontomographyrevealsacompleteremissionofrefractorymetastaticmelanomaaftertherapywithipilimumab
AT ahmadzadehfarhojjat 18ffluorodeoxyglucosepositronemissiontomographyrevealsacompleteremissionofrefractorymetastaticmelanomaaftertherapywithipilimumab

Ejemplares similares